Sacral Nerve Stimulation For The Treatment Of Refractory Overactive Bladder: Preliminary Results
Z. Liu,X. Tian,L. Ma
DOI: https://doi.org/10.3969/j.issn.1009-6604.2017.04.009
2017-01-01
Abstract:Objective To evaluate the effectiveness and safety of sacral nerve stimulation (SNS) for the treatment of refractory overactive bladder (OAB).Methods We analyzed clinical data of 9 patients with refractory OAB from May 2016 to October 2016 retrospectively.The 9 patients were treated with SNS, which consisted of experimental therapy and permanent implantation therapy.Antibiotics of third generation quinolones and second generation cephalosporins were used to prevent infection after surgery.The data of voiding diary (including average urinary frequency of 24 h in 5 d and average micturition volume of 24 h in 5 d), overactive bladder symptom score (OABSS), O'Leary-Sant problem and symptom index (OPSI), interstitial cystitis problem index (ICPI) and interstitial cystitis symptom index (ICSI) were collected.All the patients were followed up for adverse reactions related to operation, related to stimulation and related to the device.Results All the 9 cases accepted permanent implantation therapy after a period of experimental therapy with satisfactory curative effects.The success rate of permanent implantation in this group was 100%.The interval time between experimental therapy and permanent implantation therapy was 6-22 days, with an average of (9.6±5.0) days.Postoperative follow-up time ranged from 3-8 months, with an average of (6.1±1.5) months.Before the surgery, the average urinary frequency of 24 h was (34.0±16.7) times.After surgery, the data was (18.0±4.5) times.There was significant difference before and after surgery (t=3.648, P=0.007).The difference was also statistically significant (t=-4.314, P=0.003) between preoperative average micturition volume of 24 h (106.5±44.6 ml) and postoperative micturition volume (140.8±38.3 ml).Before the surgery, the OABSS, OPSI, ICPI and ICSI were (10.8±1.7), (31.6±2.4), (14.4±1.1), and (17.1±1.6) points.After surgery, the data were (6.3±3.3), (16.0±3.5), (6.8±2.5), and (9.2±2.6) points.The scores were significantly improved or the differences were statistically significant in the OABSS (t=5.946, P=0.000), OPSI (t=9.061, P=0.000), ICPI (t=7.667, P=0.000) and ICSI (t=6.475, P=0.000).Surgery related adverse reactions such as infection, bleeding, neurological or vascular injury did not occur.There were no stimulation related adverse reactions such as implantation site pain, new pain and bowel function changes, transient mild electric shock feeling and device related adverse reactions (electrode breakage, short electrode, dysfunction, part corrosion and infection).Conclusion Initial clinical results show that SNS is safe and effective for patients with refractory OAB who are not well treated by conservative treatment.